Metabolic Activation 73 2-Allylisopropylacetamide (AIA) 117F

Metabolic Activation 73 2-Allylisopropylacetamide (AIA) 117F

j377 Index a – terminal 117ff. abacavir 369f. allele association ABT, see 1-aminobenzotriazole – HLA 370 acetaminophen 71, 273ff. allopurinol 373 – metabolic activation 73 2-allylisopropylacetamide (AIA) 117f. – metabolism 72 alpidem 304f., 336, 349 acetaminophen-like metabolite 276 amanitin 204 N-acetyl-p-benzoquinone imine (NAPQI) Ames assay 29 5, 73 AMG 458 139ff. N-acetylcysteine 275 a-amidoacetonitrile 324 N-acetyltransferase (NAT) 16, 283 amine 49 N-acetyltransferase-2 (NAT-2) 79, 283 – aromatic, see aromatic amine acute liver failure (ALF) 363 – carcinogenicity of aromatic and acylating agent 320 heteroaromatic amine 13 afatinib 319 – drug–drug interaction 51 affinity label 313 amineptine 196, 342ff. aflatoxin 214 2-amino-3,8-dimethylimidazo[4,5-f] fl a atoxin B1 (AFB1)2 quinoxaline (MeIQx) 216 – bioactivation 215 – bioactivation 218 AKT inhibitor, see protein kinase B inhibitor 2-amino-1-methyl-6-phenylimidazo[4,5-b] alanine transaminase (ALT) 363 pyridine (PhIP) 216 alclofenac – bioactivation 218 – metabolic activation 119 aminoazo dye 15 aldehyde oxidase 60 1-aminobenzotriazole (ABT) 58f. alendronic acid 290 aminoglutethimide 188 alkaloid 5-aminooxindole 253 – pyrrolizidine 210 – derivative 254 alkene ortho-aminophenol 101 – terminal 117f. para-aminophenol 101 3-alkyl pyrrole 112 2-aminothiazole 109 – activation 112 amitriptyline 282ff., 343f. alkylating species 173 – metabolism 287 2-alkylimidazole 57 amlodipine 274 3-alkylindole analogue 113 amodiaquine 252 3-alkylindole derivative 112 – metabolic activation 101 alkylpiperazine 258 amoxicillin 132, 273ff., 288 alkyne 56f. angiotensin converting enzyme – bioactivation 119f. inhibitor 294ff. – internal 120 angiotensin II receptor antagonist 298 Reactive Drug Metabolites, First Edition. Amit S. Kalgutkar, Deepak Dalvie, R. Scott Obach, and Dennis A. Smith. Ó 2012 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2012 by Wiley-VCH Verlag GmbH & Co. KGaA. 378j Index anilide structural alert 299 b aniline 98, 188 benazepril 294ff. – metabolic activation 100 benzbromarone 373 aniline cancer 15 1,3-benzdioxole motif 115f. animal – metabolic activation 117 – plant–animal warfare 204 benzene oxide 4 anthracycline 157ff. benzo[a]pyrene 2 – antibiotic 158 benzodiazepine drug 297ff. – bioreductive activation 173 1,3-benzodioxole structural alert 292 anthramycin 318 benzoquinone 170 anti-HIV drug 108 – ortho-(1,2)-benzoquinone (BQ) 4 antianxiolytic drug 253 – para-(1,4)-benzoquinone (BQ) 4 antibiotic 131,158, 170, 281f., 297ff. BIBW2992 319 antibody 8 bile salt export pump (BSEP) inhibition 197, anticancer drug 21, 160 288, 348ff. – quinone-containing 21 bioactivation 203ff. antidepressant drug 253, 293, 344 – detection 233 antidiabetic agent 274, 282ff., 349 – herbal remedy 205 antihypertensive drug 297f. biomarker antimalarial agent 252 – toxicity 369 antipain 322ff. bioreduction antipsychotic 368 – adical intermediate 157 aplaviroc 366 black box warning 365 ar-tumerone 318 boceprevir 322ff. aripiprazole 343f. 2-bromo-2-chloro-1,1,1-trifluoroethane, Aristolochia 208 see halothane aristolochic acid 208 buprenorphine 300ff., 350 – bioactivation 209 buspirone 336 – metabolism 209 cis-2-butene-1,4-dial 23ff. aromatic amine 98ff. BZQ 170 – carcinogenicity 13 – metabolic activation 100 c aromatic carboxamide calcium channel antagonist 327 derivative 35 calcium receptor antagonist 36, 347 aromatic ring calcium sensing receptor (CaSR) – electron-rich 251 antagonist 346 artemisinin 166 calicheamicin 161 – bioactivation 167 calicheamicin c1 158 – derivative 166 – activation 163 arylindenopyrimidine derivative canertinib 319 – pyrrolidine-substituted 34 carbamate 320 aspartate transaminase (AST) 363 carbazilquinone 170 aspirin 322f. carboxylic acid 189 atenolol 187 carbutamide 195 atorvastatin 273 carcinogenesis 1 – metabolism 276 carcinogenic substance 14 ATPase carcinogenicity – gastric 278 – aromatic and heteroaromatic amines 13 augmentin 288 – dihaloalkane 28 azaheterocyclic compound – ethyl carbamate 26 – polycyclic 216 – furan 23 aziridinylbenzoquinone 170ff. – nitrosamine 17 – metabolic activation 172 – quinone 19 azithromycin 274 – vinyl halide 26 Index j379 carisoprodol 290 cyclophosphamide 154f. carvedilol 297 cysteine protease inhibitor 322ff. cathepsin inhibitor 324 cytochrome P450 (CYP) enzyme 1f., 16, 204 cathepsin K inhibitor 324 – bioactivation 43ff. celecoxib 193ff., 290 – inactivator 58 cephalosporin 320 – inactivation 43ff., 237 chemical reactivity 326ff. – inhibition 98 – experimental approach 326 – inhibitor 97 – in silico approach 328 – mechanism of inactivation 47 chemokine receptor type 5 (CCR5) cytotoxicity – antagonist 366 – reactive metabolite 5 – inhibitor 365 chloramphenicol 188 d 5-[3-(2-chloroethyl)-1-triazenyl]imidazole-4- dacarbazine 150 carboxamide (MCTIC) 149 daily dose trend 270 chlorpropamide 349 dapsone 188 chymostatin 322ff. DDI, see drug–drug interaction ciprofloxacin 297ff. detoxification 6 clavulanate 132 detoxification pathway clavulanic acid 321 – competing 341 clinical drug toxicity 359 diazepam 297ff. clonazepam 297ff. diaziquone 170 clopidogrel 151, 273ff. diclofenac 101 – clearance mechanism 281 – metabolic activation 102 – metabolic activation 279 dihaloalkane 28 clozapine 101, 302ff., 336ff., 368f. – bioactivation 28 – metabolic activation 103 – carcinogenicity 28 clozarilÒ 369 dipeptidyl peptidase (DPP IV) 324 co-trimoxole 282 DNA adduct 17 coltsfoot 210 DNA alkylation 94, 153 comfrey 210 – nitrogen mustard 96 concerta 290 DNA binding 3 coniine 204 DNA cleavage 162 contraindication 367 DNA cross-link formation 212 corticotropin-releasing factor-1 (CRF1) DNA-reactive metabolite receptor antagonist 253 – bioactivation of vinyl chloride 27 – pyrazinone-based 256 – bioactivation pathway of nitrosamines 18 covalent binding – bioactivation pathway of safrole 22 – reactive metabolite cytotoxicity 5 – bioactivation pathway of tamoxifen 21 covalent binding assay 231f. donepezil 300ff., 365 covalent inhibitor 313ff. dose size – reversible 326 – IADR 342 covalent modification doxorubicin – reversible 322 – bioreductive activation 173 covalent modifier drug – reversible 325 – bioreductive activation 153 CP-671,305 340 – nonenzymatically activated 145 cyanamide 324 – retrospective analysis of structure–toxicity cycasin 212f. relationship 185ff. – bioactivation 213 drug design cyclobenzaprine 292, 343 – structural alert 225, 336 – oxidative metabolism 296 drug discovery 29 cyclooxygenase-2 (COX-2)–selective – assay for metabolism-dependent inhibitor 192ff., 248 genotoxicity 28 380j Index – intrinsically electrophilic compound 131ff. – metabolic activation 301 – reactive metabolite formation 241 17a-ethinylsteroid 120 – reactive metabolite–positive ethyl carbamate 26 compound 335 – carcinogenicity 26 drug safety data 358 ezetimibe 302f. drug toxicity – rules and laws 363 f drug withdrawal 360ff. fatty acid amide hydrolase (FAAH) 322 drug–drug interaction (DDI) 46 – inhibitor 323 – amine-containing drug 51 felbamate 258ff. – cytochrome P450 time-dependent fetal hydantoin syndrome 10 inhibitor 50 fluconazole 282ff. drug-induced toxicity 4-fluorofelbamate 258ff. – reactive metabolite 71ff. fluoroquinolone antibiotic 297ff. drug-metabolizing enzyme fluoxetine 290 – bioactivation 43ff. FMS inhibitor, see tyrosine kinase inhibitor – inactivation 43ff. fosamax 290 dynemicin 163 frank electrophile 93 dynemicin A 158 furafylline 57 – bioactivation 164 furan 23, 55f. – carcinogenicity 23 e – metabolic activation 108 efavirenz 56, 121 – oxidative bioactivation 24 elastinal 322ff. – xenobiotic 107 electrophile trapping assay furosemide 282ff. – qualitative 227 – quantitative 230 g electrophilic compound gabapentin 290 – drug discovery 133ff. gefitinib 318 – drug toxicity 135 gemfibrozil 58f. – intrinsically 131ff. gemtuzumab ozogamicin 165 electrophilic functional group 94 genetic influence electrophilic intermediate – reactive metabolite formation 5 – bioreductive activation 168 genotoxicity enalapril 290ff. – drug discovery 28 enediyne 158ff. – reactive metabolite 13ff. – cycloaromatization 161 germander 205 – 9-membered ring system 160 glitazone 191 – 10-membered ring system 160 glutathione (GSH) 3, 207, 229f., 249 entacapone 338f. – electrophilic compound 134ff. enzyme kinetic principle glutathione transferase 28 – mechanism-based inactivation 44 glyburide 282ff., 349 epidermal growth factor receptor (EGFR) 317 – covalent EGFR inhibitor 319 h 1,2-epoxy-3,3,3-trichloropropane (TCPO) 10 halothane 7, 75ff. erlotinib 318 – hepatotoxicity 78 escitalopram 274 – metabolism 76 esomeprazole 273ff. – oxidative metabolism 77 esperamicins A1 158 – reactive metabolites in immune-mediated ester 320 toxicity 7 estradiol – reductive metabolism 77 – metabolism 20 helenalin 318 ethinylestradiol 56, 297, 350 heme adduct 48 – 17a-ethinylestradiol 120 hepatotoxicant 4 Index j381 hepatotoxicity 186 – covalent 315ff. – halothane administration 78 – irreversible 314 herbal remedy 205 – irreversible warhead 317 – bioactivation 205 – kinetic description 44 herbimycin A 318 – mechanism-based 198 heteroaromatic amine 13 intoxication 6 – carcinogenicity 13 isoniazid 60 heteroaromatic nitrile 324 – metabolic activation 106 heteroaromatic ring isosorbide mononitrate 290 – five-membered 107 isothiazole ring bioactivation 249f. heterocyclic ring system 242 N,N,N0,N0,N00,N00- j hexamethylmelamine 153ff. januvia 290 human leukocyte antigen (HLA) 370f. hydralazine 60, 79 k – metabolic activation 81 ketoconazole 349 – metabolism 80 kinase inhibitor hydrazine 105 – irreversible 319 hydrochlorothiazide 294 – reversible

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    10 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us